Review



t cells  (Bio X Cell)


Bioz Verified Symbol Bio X Cell is a verified supplier
Bioz Manufacturer Symbol Bio X Cell manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Bio X Cell t cells
    T Cells, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 95/100, based on 98 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/thy1+2/InVivoMAb+anti-mouse+Thy1%2E2/pm42816625-560-21-24
    Average 95 stars, based on 98 article reviews
    t cells - by Bioz Stars, 2026-11
    95/100 stars

    Images

    Related Articles

    other:

    Article Title: Commensal Cryptosporidium colonization elicits a cDC1-dependent Th1 response that promotes intestinal homeostasis and limits other infections.
    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies anti-IFNg Clone H22 Leinco Cat#I-438 PIP Leinco Cat#P-376 anti-Thy1.2 clone 30H12 BioXCell Cat#BE0066 LTF-2 BioXCell Cat#BE0090 anti-NK1.1 clone PK136 BioXCell Cat##BE0036 C1.18.4 BioXCell Cat#BE0085 anti-IL10R BioXCell Cat#BE0050 anti-CD3ε BioXCell Cat#BE0001-1 anti-MHCII BioXCell Cat#BE010 anti-CD28 BioXCell Cat#BE0015-1 anti-TGFb BioXCell Cat#BE0057 anti-IL-12 BioXCell Cat#BE0052 anti-IFNg BioXCell Cat#BE0054 anti-IL-4 BioXCell Cat#BE0045 Anti-mouse CD3ε (clone#145-2C11) FITC, PE, and BV421 BioLegend Cat#100305/07/35 Anti-mouse/human B220 (clone#RA3-6B2) APC/Cy7, A700, and PE/Cy7 BioLegend Cat#103223/31/22 Anti-mouse CD19 (clone#6D5) APC/Cy7 BioLegend Cat#115529 Anti-mouse I-Ab (clone#AF6-120.1) APC and PerCP/Cy5.5 BioLegend Cat#116417/15 Anti-mouse CD11c (clone#N418) PE/Cy7 and BV605 BioLegend Cat#117317/33 Anti-mouse/human CD11b (clone#M1/ 70) BV711 BioLegend Cat#101241 Anti-mouse CD103 (clone#2E7) BV421 BioLegend Cat#121421 Anti-mouse F4/80 (clone#BM8) PE/Cy7 BioLegend Cat#123113 Anti-mouseCD4 (clone#RM4-5) BV711, PE, PB, and BV605 BioLegend Cat#100549/11/34/48 Anti-mouse CD25 (clone#PC61) APC, BV605, PerCP/Cy5.5, and PE/Cy7 BioLegend Cat#102011/35/29/15 Anti-mouse/human CD44 (clone#IM7) APC/ Cy7 and BV605 BioLegend Cat#103027/47 Anti-mouse CD62L (clone#MEL-14) APC/ Cy7 and BV605 BioLegend Cat#104427/37 Anti-mouse FOXP3 (clone#FJK-16 s) FITC ThermoFisher Cat#11-5773-82 Anti-mouse GATA3 (clone#16E10A23) PE BioLegend Cat#653803 Anti-mouse RORgt (clone#B2D) APC ThermoFisher Cat#17-6981-80 Anti-mouse TBET (clone#4B10) PE/Cy7 BioLegend Cat#644823 Anti-mouse CXCR3 (clone#CXCR3-173) BV421, PE, and APC BioLegend Cat#126521/06/12 Anti-mouse Thy1.1 (clone#OX-7) BV711, PE/Cy7, and PerCP/Cy5.5 BioLegend Cat#202539/18/16 Anti-mouse CD80 (clone#16-10A1) APC BioLegend Cat#104713 Anti-mouse CD45.1 (clone#A20) PerCP/ Cy5.5, PE, and A700 BioLegend Cat#110728/08/24 (Continued on next page) Immunity 54, 2547–2564.e1–e7, November 9, 2021 e1

    In Vivo:

    Article Title: Commensal Cryptosporidium colonization elicits a cDC1-dependent Th1 response that promotes intestinal homeostasis and limits other infections.
    Article Snippet: PCR products were sequenced using the Illumina MiSeq platform (2x250-bp paired-end reads), and ASVs and taxonomy including species designations if possible (silva 1.32) determined by dada2 (Callahan et al., 2016). .. ASV data were analyzed by phyloseq (v1.32), vegan (v2.4), and DESeq2 (v.1.28) in R (3.6) In vivo antibody treatment, oral tolerance, colon cytokine analysis, Citrobacter rodentium infection, DSS + anti-IL10R treatment, and antibiotic treatment Where indicated, mice were treated IP with weekly 250 mg anti-IFNg blocking antibody clone H22 (Leinco #I-438), 250 mg H22 isotype control clone PIP (Leinco #P-376), 500 mg anti-Thy1.2 clone 30H12 (BioXCell #BE0066), 500 mg 30H12 IgG2b isotype control clone LTF-2 (BioXCell #BE0090), 200 mg anti-NK1.1 clone PK136 (BioXCell #BE0036), or 200 mg PK136 isotype control IgG2a cloneC1.18.4 (BioXCell #BE0085). ..

    Infection:

    Article Title: Commensal Cryptosporidium colonization elicits a cDC1-dependent Th1 response that promotes intestinal homeostasis and limits other infections.
    Article Snippet: PCR products were sequenced using the Illumina MiSeq platform (2x250-bp paired-end reads), and ASVs and taxonomy including species designations if possible (silva 1.32) determined by dada2 (Callahan et al., 2016). .. ASV data were analyzed by phyloseq (v1.32), vegan (v2.4), and DESeq2 (v.1.28) in R (3.6) In vivo antibody treatment, oral tolerance, colon cytokine analysis, Citrobacter rodentium infection, DSS + anti-IL10R treatment, and antibiotic treatment Where indicated, mice were treated IP with weekly 250 mg anti-IFNg blocking antibody clone H22 (Leinco #I-438), 250 mg H22 isotype control clone PIP (Leinco #P-376), 500 mg anti-Thy1.2 clone 30H12 (BioXCell #BE0066), 500 mg 30H12 IgG2b isotype control clone LTF-2 (BioXCell #BE0090), 200 mg anti-NK1.1 clone PK136 (BioXCell #BE0036), or 200 mg PK136 isotype control IgG2a cloneC1.18.4 (BioXCell #BE0085). ..

    Article Title: Lung tissue-resident memory T cells optimize protection by IL-10 regulation of innate immunity
    Article Snippet: .. To deplete T RM from mice, WT mice were infected with X31 influenza virus as above and 3 weeks post infection (wkpi), the resultant memory mice were administered 10μg/g of Thy1.2-depleting antibody (BioXcell; BE0066) by intraperitoneal (IP) injection four times over the course of one week. .. To deplete T RM from mice, WT mice were infected with X31 influenza virus as above and 3 weeks post infection (wkpi), the resultant memory mice were administered 10μg/g of Thy1.2-depleting antibody (BioXcell; BE0066) by intraperitoneal (IP) injection four times over the course of one week.

    Blocking Assay:

    Article Title: Commensal Cryptosporidium colonization elicits a cDC1-dependent Th1 response that promotes intestinal homeostasis and limits other infections.
    Article Snippet: PCR products were sequenced using the Illumina MiSeq platform (2x250-bp paired-end reads), and ASVs and taxonomy including species designations if possible (silva 1.32) determined by dada2 (Callahan et al., 2016). .. ASV data were analyzed by phyloseq (v1.32), vegan (v2.4), and DESeq2 (v.1.28) in R (3.6) In vivo antibody treatment, oral tolerance, colon cytokine analysis, Citrobacter rodentium infection, DSS + anti-IL10R treatment, and antibiotic treatment Where indicated, mice were treated IP with weekly 250 mg anti-IFNg blocking antibody clone H22 (Leinco #I-438), 250 mg H22 isotype control clone PIP (Leinco #P-376), 500 mg anti-Thy1.2 clone 30H12 (BioXCell #BE0066), 500 mg 30H12 IgG2b isotype control clone LTF-2 (BioXCell #BE0090), 200 mg anti-NK1.1 clone PK136 (BioXCell #BE0036), or 200 mg PK136 isotype control IgG2a cloneC1.18.4 (BioXCell #BE0085). ..

    Control:

    Article Title: Commensal Cryptosporidium colonization elicits a cDC1-dependent Th1 response that promotes intestinal homeostasis and limits other infections.
    Article Snippet: PCR products were sequenced using the Illumina MiSeq platform (2x250-bp paired-end reads), and ASVs and taxonomy including species designations if possible (silva 1.32) determined by dada2 (Callahan et al., 2016). .. ASV data were analyzed by phyloseq (v1.32), vegan (v2.4), and DESeq2 (v.1.28) in R (3.6) In vivo antibody treatment, oral tolerance, colon cytokine analysis, Citrobacter rodentium infection, DSS + anti-IL10R treatment, and antibiotic treatment Where indicated, mice were treated IP with weekly 250 mg anti-IFNg blocking antibody clone H22 (Leinco #I-438), 250 mg H22 isotype control clone PIP (Leinco #P-376), 500 mg anti-Thy1.2 clone 30H12 (BioXCell #BE0066), 500 mg 30H12 IgG2b isotype control clone LTF-2 (BioXCell #BE0090), 200 mg anti-NK1.1 clone PK136 (BioXCell #BE0036), or 200 mg PK136 isotype control IgG2a cloneC1.18.4 (BioXCell #BE0085). ..

    Article Title: Disruption of the endopeptidase ADAM10-Notch signaling axis leads to skin dysbiosis and innate lymphoid cell-mediated hair follicle destruction.
    Article Snippet: .. Thy1.2 (IgG2b, clone 30H12; Bio X cell) or isotype control (IgG2b, clone LTF-2; Bio X cell) were administered subcutaneously in ADAM10DMx1 Rag2–/– mice into the upper chest area twice weekly at a dose of 250 mg /mouse starting at day 0 of poly(I:C) administration. .. Mouse CCL20/MIP-3 alpha Antibody (R&D) or isotype control (IgG1 Isotype control) were administered subcutaneously in ADAM10DMx1 mice into the upper chest area at a dose of 100 ug/mouse for 3 days starting at day 17 of poly(I:C) administration.

    Article Title: Interleukin-7 Availability Is Maintained by a Hematopoietic Cytokine Sink Comprising Innate Lymphoid Cells and T Cells.
    Article Snippet: Anti-Thy1.2, clone 30H-12, and isotype control (LTF-2), anti-NK1.1 (PK136) and anti-CD90.2 (19E12) were purchased from Bio X Cell (West Lebanon, NH). .. Anti-Thy1.2, clone 30H-12, and isotype control (LTF-2), anti-NK1.1 (PK136) and anti-CD90.2 (19E12) were purchased from Bio X Cell (West Lebanon, NH). ..

    Article Title: IgD + Age-Associated B cells are the progenitors of the main T-independent B cell response to infection that generates protective Ab and can be induced by an inactivated vaccine in the aged
    Article Snippet: .. In some experiments young and aged mice were treated i.p. with 250 μg of either anti–Thy1.2-depleting antibody (30-H12) (Bio X Cell) or with an isotype control on 0 DPI and 7 DPI( ). ..

    Virus:

    Article Title: Lung tissue-resident memory T cells optimize protection by IL-10 regulation of innate immunity
    Article Snippet: .. To deplete T RM from mice, WT mice were infected with X31 influenza virus as above and 3 weeks post infection (wkpi), the resultant memory mice were administered 10μg/g of Thy1.2-depleting antibody (BioXcell; BE0066) by intraperitoneal (IP) injection four times over the course of one week. .. To deplete T RM from mice, WT mice were infected with X31 influenza virus as above and 3 weeks post infection (wkpi), the resultant memory mice were administered 10μg/g of Thy1.2-depleting antibody (BioXcell; BE0066) by intraperitoneal (IP) injection four times over the course of one week.

    Injection:

    Article Title: Lung tissue-resident memory T cells optimize protection by IL-10 regulation of innate immunity
    Article Snippet: .. To deplete T RM from mice, WT mice were infected with X31 influenza virus as above and 3 weeks post infection (wkpi), the resultant memory mice were administered 10μg/g of Thy1.2-depleting antibody (BioXcell; BE0066) by intraperitoneal (IP) injection four times over the course of one week. .. To deplete T RM from mice, WT mice were infected with X31 influenza virus as above and 3 weeks post infection (wkpi), the resultant memory mice were administered 10μg/g of Thy1.2-depleting antibody (BioXcell; BE0066) by intraperitoneal (IP) injection four times over the course of one week.



    Similar Products

    95
    Bio X Cell t cells
    T Cells, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/thy1+2/InVivoMAb+anti-mouse+Thy1%2E2/pm42816625-560-21-24
    Average 95 stars, based on 1 article reviews
    t cells - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    95
    Bio X Cell anti cd90 2
    Anti Cd90 2, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/thy1+2/InVivoMAb+anti-mouse+Thy1%2E2/pm41896941-45-10-11
    Average 95 stars, based on 1 article reviews
    anti cd90 2 - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    86
    Charles River Laboratories female cd45 2 thy1 2 c57bl 6
    Female Cd45 2 Thy1 2 C57bl 6, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/thy1+2/balb+c+mice/pm41758652-259-2-24
    Average 86 stars, based on 1 article reviews
    female cd45 2 thy1 2 c57bl 6 - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    86
    Jackson Laboratory thy1 2 c57bl 6 c57bl 6j mice
    ( A-B ) Mouse CD8+ T cells were treated with indicated cytokines for 24 hours prior to RNA isolation for bulk RNAseq analysis; (A) Geneset enrichment analysis (GSEA) for DEGs between IL-2/21-Trikine-treated vs sIL2-treated mouse CD8+ T cells (left) and heatmap of leading-edge genes (right). The DEG ranks were projected onto two gene sets defined based on a previously published ChIP-seq data . pSTAT3-promoted genes, genes with stronger ChIP peaks in STAT3-WT mice. (B) Relative expression of stemness genes Tcf7 , Bach2 , Il7r , Slamf6 , and Sell between mouse CD8+ T cells treated with either sIL-2 or IL-2/21-Trikine. Results from one independent experiment with 3 technical replicates. ( C-F <t>),</t> <t>C57BL/6</t> mice bearing established s.c. B16F10 tumors received intravenous (i.v.) adoptive cell transfer (ACT) of pmel CD8+ T cells (1 x 10 7 ) that were preconditioned for 7 days with sIL-2, sIL-2 + IL-21, or IL-2/21-Trikine on day 5, followed by i.p. injections of cytokine (5 μg functional cytokine) every other day until day 12 (n = 5 animals); the experimental timeline (C), average tumor growth curves (D), average weight change curves (E), and survival curves (F). Results from one independent experiment. ( G-I ) Healthy C57BL/6 mice were dosed with 10 μg functional dose of sIL-2, IL-21, sIL-2 + IL-21, IL-2/21-Trikine or PBS every other day for four total doses (n = 10 mice); experimental timeline (G) percent weight change at study endpoint (H), serum amyloid A concentrations at study endpoint (I). Results are combined from 2 independent experiments. ( J-M ), C57BL/6 mice bearing established s.c. B16F10 tumors received intravenous (i.v.) adoptive cell transfer (ACT) of pmel CD8+ T cells (1 x 10 7 ) that were preconditioned for 7 days with sIL-2, sIL-2 + IL-21, or IL-2/21-Trikine on day 5, followed by i.p. injections of cytokine (2.5 μg functional cytokine) every other day until day 12 (n = 14/15 animals); the experimental timeline (J), average tumor growth curves (K), average weight change curves (L), and survival curves (M). Results are combined from 2 independent experiments. ( N ) Proportions of pmel T cell memory populations, TCM and TEM in the draining lymph node 16 days post tumor injection from mice receiving low dose regimen (J-M) (n = 8). Results representative of 2 independent experiments. ( O-P ) MFI of Sca1 (O) and IL7Ra (P) cells in the draining lymph node 12 days post ACT compared to on the day of ACT from mice receiving low dose regimen (J) (n = 8). Results representative of 2 independent experiments. ( Q ) Intratumoral, live <t>Thy1.1+CD8+</t> cells were sorted from dissociated tumor 12 days after ACT as in (J) and sent for scRNA-seq. 8 transcriptionally distinct clusters are seen by UMAP (left) and cluster composition by treatment is displayed (right). scRNAseq data is from one independent experiment. Schematics in C, G, and J created using BioRender.com .
    Thy1 2 C57bl 6 C57bl 6j Mice, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/thy1+2/a+b6+cyj+pl+thy1/pmc12963926-299-9-23
    Average 86 stars, based on 1 article reviews
    thy1 2 c57bl 6 c57bl 6j mice - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    95
    Bio X Cell be0146 rrid ab 10949053 invivomab anti mouse thy1 2 cd90 2 bioxcell
    ( A-B ) Mouse CD8+ T cells were treated with indicated cytokines for 24 hours prior to RNA isolation for bulk RNAseq analysis; (A) Geneset enrichment analysis (GSEA) for DEGs between IL-2/21-Trikine-treated vs sIL2-treated mouse CD8+ T cells (left) and heatmap of leading-edge genes (right). The DEG ranks were projected onto two gene sets defined based on a previously published ChIP-seq data . pSTAT3-promoted genes, genes with stronger ChIP peaks in STAT3-WT mice. (B) Relative expression of stemness genes Tcf7 , Bach2 , Il7r , Slamf6 , and Sell between mouse CD8+ T cells treated with either sIL-2 or IL-2/21-Trikine. Results from one independent experiment with 3 technical replicates. ( C-F <t>),</t> <t>C57BL/6</t> mice bearing established s.c. B16F10 tumors received intravenous (i.v.) adoptive cell transfer (ACT) of pmel CD8+ T cells (1 x 10 7 ) that were preconditioned for 7 days with sIL-2, sIL-2 + IL-21, or IL-2/21-Trikine on day 5, followed by i.p. injections of cytokine (5 μg functional cytokine) every other day until day 12 (n = 5 animals); the experimental timeline (C), average tumor growth curves (D), average weight change curves (E), and survival curves (F). Results from one independent experiment. ( G-I ) Healthy C57BL/6 mice were dosed with 10 μg functional dose of sIL-2, IL-21, sIL-2 + IL-21, IL-2/21-Trikine or PBS every other day for four total doses (n = 10 mice); experimental timeline (G) percent weight change at study endpoint (H), serum amyloid A concentrations at study endpoint (I). Results are combined from 2 independent experiments. ( J-M ), C57BL/6 mice bearing established s.c. B16F10 tumors received intravenous (i.v.) adoptive cell transfer (ACT) of pmel CD8+ T cells (1 x 10 7 ) that were preconditioned for 7 days with sIL-2, sIL-2 + IL-21, or IL-2/21-Trikine on day 5, followed by i.p. injections of cytokine (2.5 μg functional cytokine) every other day until day 12 (n = 14/15 animals); the experimental timeline (J), average tumor growth curves (K), average weight change curves (L), and survival curves (M). Results are combined from 2 independent experiments. ( N ) Proportions of pmel T cell memory populations, TCM and TEM in the draining lymph node 16 days post tumor injection from mice receiving low dose regimen (J-M) (n = 8). Results representative of 2 independent experiments. ( O-P ) MFI of Sca1 (O) and IL7Ra (P) cells in the draining lymph node 12 days post ACT compared to on the day of ACT from mice receiving low dose regimen (J) (n = 8). Results representative of 2 independent experiments. ( Q ) Intratumoral, live <t>Thy1.1+CD8+</t> cells were sorted from dissociated tumor 12 days after ACT as in (J) and sent for scRNA-seq. 8 transcriptionally distinct clusters are seen by UMAP (left) and cluster composition by treatment is displayed (right). scRNAseq data is from one independent experiment. Schematics in C, G, and J created using BioRender.com .
    Be0146 Rrid Ab 10949053 Invivomab Anti Mouse Thy1 2 Cd90 2 Bioxcell, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/thy1+2/InVivoMAb+anti-mouse+Thy1%2E2/pm41564868-279-89-95
    Average 95 stars, based on 1 article reviews
    be0146 rrid ab 10949053 invivomab anti mouse thy1 2 cd90 2 bioxcell - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    95
    Bio X Cell invivomab anti mouse thy1 2
    ( A-B ) Mouse CD8+ T cells were treated with indicated cytokines for 24 hours prior to RNA isolation for bulk RNAseq analysis; (A) Geneset enrichment analysis (GSEA) for DEGs between IL-2/21-Trikine-treated vs sIL2-treated mouse CD8+ T cells (left) and heatmap of leading-edge genes (right). The DEG ranks were projected onto two gene sets defined based on a previously published ChIP-seq data . pSTAT3-promoted genes, genes with stronger ChIP peaks in STAT3-WT mice. (B) Relative expression of stemness genes Tcf7 , Bach2 , Il7r , Slamf6 , and Sell between mouse CD8+ T cells treated with either sIL-2 or IL-2/21-Trikine. Results from one independent experiment with 3 technical replicates. ( C-F <t>),</t> <t>C57BL/6</t> mice bearing established s.c. B16F10 tumors received intravenous (i.v.) adoptive cell transfer (ACT) of pmel CD8+ T cells (1 x 10 7 ) that were preconditioned for 7 days with sIL-2, sIL-2 + IL-21, or IL-2/21-Trikine on day 5, followed by i.p. injections of cytokine (5 μg functional cytokine) every other day until day 12 (n = 5 animals); the experimental timeline (C), average tumor growth curves (D), average weight change curves (E), and survival curves (F). Results from one independent experiment. ( G-I ) Healthy C57BL/6 mice were dosed with 10 μg functional dose of sIL-2, IL-21, sIL-2 + IL-21, IL-2/21-Trikine or PBS every other day for four total doses (n = 10 mice); experimental timeline (G) percent weight change at study endpoint (H), serum amyloid A concentrations at study endpoint (I). Results are combined from 2 independent experiments. ( J-M ), C57BL/6 mice bearing established s.c. B16F10 tumors received intravenous (i.v.) adoptive cell transfer (ACT) of pmel CD8+ T cells (1 x 10 7 ) that were preconditioned for 7 days with sIL-2, sIL-2 + IL-21, or IL-2/21-Trikine on day 5, followed by i.p. injections of cytokine (2.5 μg functional cytokine) every other day until day 12 (n = 14/15 animals); the experimental timeline (J), average tumor growth curves (K), average weight change curves (L), and survival curves (M). Results are combined from 2 independent experiments. ( N ) Proportions of pmel T cell memory populations, TCM and TEM in the draining lymph node 16 days post tumor injection from mice receiving low dose regimen (J-M) (n = 8). Results representative of 2 independent experiments. ( O-P ) MFI of Sca1 (O) and IL7Ra (P) cells in the draining lymph node 12 days post ACT compared to on the day of ACT from mice receiving low dose regimen (J) (n = 8). Results representative of 2 independent experiments. ( Q ) Intratumoral, live <t>Thy1.1+CD8+</t> cells were sorted from dissociated tumor 12 days after ACT as in (J) and sent for scRNA-seq. 8 transcriptionally distinct clusters are seen by UMAP (left) and cluster composition by treatment is displayed (right). scRNAseq data is from one independent experiment. Schematics in C, G, and J created using BioRender.com .
    Invivomab Anti Mouse Thy1 2, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/thy1+2/InVivoMAb+anti-mouse+Thy1%2E2/pmc12866125-13-0-5
    Average 95 stars, based on 1 article reviews
    invivomab anti mouse thy1 2 - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    95
    Bio X Cell be0066 rrid ab 1107682
    ( A-B ) Mouse CD8+ T cells were treated with indicated cytokines for 24 hours prior to RNA isolation for bulk RNAseq analysis; (A) Geneset enrichment analysis (GSEA) for DEGs between IL-2/21-Trikine-treated vs sIL2-treated mouse CD8+ T cells (left) and heatmap of leading-edge genes (right). The DEG ranks were projected onto two gene sets defined based on a previously published ChIP-seq data . pSTAT3-promoted genes, genes with stronger ChIP peaks in STAT3-WT mice. (B) Relative expression of stemness genes Tcf7 , Bach2 , Il7r , Slamf6 , and Sell between mouse CD8+ T cells treated with either sIL-2 or IL-2/21-Trikine. Results from one independent experiment with 3 technical replicates. ( C-F <t>),</t> <t>C57BL/6</t> mice bearing established s.c. B16F10 tumors received intravenous (i.v.) adoptive cell transfer (ACT) of pmel CD8+ T cells (1 x 10 7 ) that were preconditioned for 7 days with sIL-2, sIL-2 + IL-21, or IL-2/21-Trikine on day 5, followed by i.p. injections of cytokine (5 μg functional cytokine) every other day until day 12 (n = 5 animals); the experimental timeline (C), average tumor growth curves (D), average weight change curves (E), and survival curves (F). Results from one independent experiment. ( G-I ) Healthy C57BL/6 mice were dosed with 10 μg functional dose of sIL-2, IL-21, sIL-2 + IL-21, IL-2/21-Trikine or PBS every other day for four total doses (n = 10 mice); experimental timeline (G) percent weight change at study endpoint (H), serum amyloid A concentrations at study endpoint (I). Results are combined from 2 independent experiments. ( J-M ), C57BL/6 mice bearing established s.c. B16F10 tumors received intravenous (i.v.) adoptive cell transfer (ACT) of pmel CD8+ T cells (1 x 10 7 ) that were preconditioned for 7 days with sIL-2, sIL-2 + IL-21, or IL-2/21-Trikine on day 5, followed by i.p. injections of cytokine (2.5 μg functional cytokine) every other day until day 12 (n = 14/15 animals); the experimental timeline (J), average tumor growth curves (K), average weight change curves (L), and survival curves (M). Results are combined from 2 independent experiments. ( N ) Proportions of pmel T cell memory populations, TCM and TEM in the draining lymph node 16 days post tumor injection from mice receiving low dose regimen (J-M) (n = 8). Results representative of 2 independent experiments. ( O-P ) MFI of Sca1 (O) and IL7Ra (P) cells in the draining lymph node 12 days post ACT compared to on the day of ACT from mice receiving low dose regimen (J) (n = 8). Results representative of 2 independent experiments. ( Q ) Intratumoral, live <t>Thy1.1+CD8+</t> cells were sorted from dissociated tumor 12 days after ACT as in (J) and sent for scRNA-seq. 8 transcriptionally distinct clusters are seen by UMAP (left) and cluster composition by treatment is displayed (right). scRNAseq data is from one independent experiment. Schematics in C, G, and J created using BioRender.com .
    Be0066 Rrid Ab 1107682, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/thy1+2/InVivoMAb+anti-mouse+Thy1%2E2/pmc12866125-13-8-5
    Average 95 stars, based on 1 article reviews
    be0066 rrid ab 1107682 - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    95
    Bio X Cell cd90 2
    ( A-B ) Mouse CD8+ T cells were treated with indicated cytokines for 24 hours prior to RNA isolation for bulk RNAseq analysis; (A) Geneset enrichment analysis (GSEA) for DEGs between IL-2/21-Trikine-treated vs sIL2-treated mouse CD8+ T cells (left) and heatmap of leading-edge genes (right). The DEG ranks were projected onto two gene sets defined based on a previously published ChIP-seq data . pSTAT3-promoted genes, genes with stronger ChIP peaks in STAT3-WT mice. (B) Relative expression of stemness genes Tcf7 , Bach2 , Il7r , Slamf6 , and Sell between mouse CD8+ T cells treated with either sIL-2 or IL-2/21-Trikine. Results from one independent experiment with 3 technical replicates. ( C-F <t>),</t> <t>C57BL/6</t> mice bearing established s.c. B16F10 tumors received intravenous (i.v.) adoptive cell transfer (ACT) of pmel CD8+ T cells (1 x 10 7 ) that were preconditioned for 7 days with sIL-2, sIL-2 + IL-21, or IL-2/21-Trikine on day 5, followed by i.p. injections of cytokine (5 μg functional cytokine) every other day until day 12 (n = 5 animals); the experimental timeline (C), average tumor growth curves (D), average weight change curves (E), and survival curves (F). Results from one independent experiment. ( G-I ) Healthy C57BL/6 mice were dosed with 10 μg functional dose of sIL-2, IL-21, sIL-2 + IL-21, IL-2/21-Trikine or PBS every other day for four total doses (n = 10 mice); experimental timeline (G) percent weight change at study endpoint (H), serum amyloid A concentrations at study endpoint (I). Results are combined from 2 independent experiments. ( J-M ), C57BL/6 mice bearing established s.c. B16F10 tumors received intravenous (i.v.) adoptive cell transfer (ACT) of pmel CD8+ T cells (1 x 10 7 ) that were preconditioned for 7 days with sIL-2, sIL-2 + IL-21, or IL-2/21-Trikine on day 5, followed by i.p. injections of cytokine (2.5 μg functional cytokine) every other day until day 12 (n = 14/15 animals); the experimental timeline (J), average tumor growth curves (K), average weight change curves (L), and survival curves (M). Results are combined from 2 independent experiments. ( N ) Proportions of pmel T cell memory populations, TCM and TEM in the draining lymph node 16 days post tumor injection from mice receiving low dose regimen (J-M) (n = 8). Results representative of 2 independent experiments. ( O-P ) MFI of Sca1 (O) and IL7Ra (P) cells in the draining lymph node 12 days post ACT compared to on the day of ACT from mice receiving low dose regimen (J) (n = 8). Results representative of 2 independent experiments. ( Q ) Intratumoral, live <t>Thy1.1+CD8+</t> cells were sorted from dissociated tumor 12 days after ACT as in (J) and sent for scRNA-seq. 8 transcriptionally distinct clusters are seen by UMAP (left) and cluster composition by treatment is displayed (right). scRNAseq data is from one independent experiment. Schematics in C, G, and J created using BioRender.com .
    Cd90 2, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/thy1+2/InVivoMAb+anti-mouse+Thy1%2E2/10__1158_slash_0008___5472__can___25___3092-122-52-57
    Average 95 stars, based on 1 article reviews
    cd90 2 - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    95
    Bio X Cell thy1 2
    (A) Quantification of total CD4 + and CD8 + T cells in the lungs of mice treated with <t>anti-Thy1.2</t> depleting Abs (orange) or IgG control Abs (gray). Statistical significance was determined by the student’s t-test. Boxes indicate interquartile range with a line drawn at the mean; whiskers indicate the minimum and maximum values. (B) T RM content in the lungs of T cell-depleted or control mice in (A) shown in representative flow cytometry plots (left) and compiled results (right) of CD45 expression from i.v. Ab administration (CD45(IV), left) and CD69 expression (right) by CD4 + (top), and CD8 + (bottom) T cells. (C) Lung macrophage accumulation after influenza infection in T RM -depleted (blue) and control (green) mice undergoing secondary infection at 4dpi compared to uninfected counterparts shown in representative flow cytometry plots (left) and compiled results (right) of F4/80 + macrophages in the lungs. Statistical significance for (A-C) was determined by the student’s t-test. (D-E) Pearson correlation analyses between T RM and CD4 + and CD8 + T RM subsets with (D) macrophages and with (E) Arg1 + macrophages. Data are representative of two independent experiments, with n=7–10 mice per group. ****, p ≤ 0.0001; ***; p ≤ 0.001; **, p ≤ 0.01; *, p ≤ 0.05.
    Thy1 2, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/thy1+2/InVivoMAb+anti-mouse+Thy1%2E2/pmc12857907-443-30-32
    Average 95 stars, based on 1 article reviews
    thy1 2 - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec cd90 2 thy1 microbeads
    (A) Quantification of total CD4 + and CD8 + T cells in the lungs of mice treated with <t>anti-Thy1.2</t> depleting Abs (orange) or IgG control Abs (gray). Statistical significance was determined by the student’s t-test. Boxes indicate interquartile range with a line drawn at the mean; whiskers indicate the minimum and maximum values. (B) T RM content in the lungs of T cell-depleted or control mice in (A) shown in representative flow cytometry plots (left) and compiled results (right) of CD45 expression from i.v. Ab administration (CD45(IV), left) and CD69 expression (right) by CD4 + (top), and CD8 + (bottom) T cells. (C) Lung macrophage accumulation after influenza infection in T RM -depleted (blue) and control (green) mice undergoing secondary infection at 4dpi compared to uninfected counterparts shown in representative flow cytometry plots (left) and compiled results (right) of F4/80 + macrophages in the lungs. Statistical significance for (A-C) was determined by the student’s t-test. (D-E) Pearson correlation analyses between T RM and CD4 + and CD8 + T RM subsets with (D) macrophages and with (E) Arg1 + macrophages. Data are representative of two independent experiments, with n=7–10 mice per group. ****, p ≤ 0.0001; ***; p ≤ 0.001; **, p ≤ 0.01; *, p ≤ 0.05.
    Cd90 2 Thy1 Microbeads, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/thy1+2/CD90%2E2+MicroBeads%2C+mouse/pmc12758515-324-11-14
    Average 96 stars, based on 1 article reviews
    cd90 2 thy1 microbeads - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    Image Search Results


    ( A-B ) Mouse CD8+ T cells were treated with indicated cytokines for 24 hours prior to RNA isolation for bulk RNAseq analysis; (A) Geneset enrichment analysis (GSEA) for DEGs between IL-2/21-Trikine-treated vs sIL2-treated mouse CD8+ T cells (left) and heatmap of leading-edge genes (right). The DEG ranks were projected onto two gene sets defined based on a previously published ChIP-seq data . pSTAT3-promoted genes, genes with stronger ChIP peaks in STAT3-WT mice. (B) Relative expression of stemness genes Tcf7 , Bach2 , Il7r , Slamf6 , and Sell between mouse CD8+ T cells treated with either sIL-2 or IL-2/21-Trikine. Results from one independent experiment with 3 technical replicates. ( C-F ), C57BL/6 mice bearing established s.c. B16F10 tumors received intravenous (i.v.) adoptive cell transfer (ACT) of pmel CD8+ T cells (1 x 10 7 ) that were preconditioned for 7 days with sIL-2, sIL-2 + IL-21, or IL-2/21-Trikine on day 5, followed by i.p. injections of cytokine (5 μg functional cytokine) every other day until day 12 (n = 5 animals); the experimental timeline (C), average tumor growth curves (D), average weight change curves (E), and survival curves (F). Results from one independent experiment. ( G-I ) Healthy C57BL/6 mice were dosed with 10 μg functional dose of sIL-2, IL-21, sIL-2 + IL-21, IL-2/21-Trikine or PBS every other day for four total doses (n = 10 mice); experimental timeline (G) percent weight change at study endpoint (H), serum amyloid A concentrations at study endpoint (I). Results are combined from 2 independent experiments. ( J-M ), C57BL/6 mice bearing established s.c. B16F10 tumors received intravenous (i.v.) adoptive cell transfer (ACT) of pmel CD8+ T cells (1 x 10 7 ) that were preconditioned for 7 days with sIL-2, sIL-2 + IL-21, or IL-2/21-Trikine on day 5, followed by i.p. injections of cytokine (2.5 μg functional cytokine) every other day until day 12 (n = 14/15 animals); the experimental timeline (J), average tumor growth curves (K), average weight change curves (L), and survival curves (M). Results are combined from 2 independent experiments. ( N ) Proportions of pmel T cell memory populations, TCM and TEM in the draining lymph node 16 days post tumor injection from mice receiving low dose regimen (J-M) (n = 8). Results representative of 2 independent experiments. ( O-P ) MFI of Sca1 (O) and IL7Ra (P) cells in the draining lymph node 12 days post ACT compared to on the day of ACT from mice receiving low dose regimen (J) (n = 8). Results representative of 2 independent experiments. ( Q ) Intratumoral, live Thy1.1+CD8+ cells were sorted from dissociated tumor 12 days after ACT as in (J) and sent for scRNA-seq. 8 transcriptionally distinct clusters are seen by UMAP (left) and cluster composition by treatment is displayed (right). scRNAseq data is from one independent experiment. Schematics in C, G, and J created using BioRender.com .

    Journal: Science (New York, N.Y.)

    Article Title: Rewiring STAT signaling from the cell surface with Trikine immunotherapeutics

    doi: 10.1126/science.adx9954

    Figure Lengend Snippet: ( A-B ) Mouse CD8+ T cells were treated with indicated cytokines for 24 hours prior to RNA isolation for bulk RNAseq analysis; (A) Geneset enrichment analysis (GSEA) for DEGs between IL-2/21-Trikine-treated vs sIL2-treated mouse CD8+ T cells (left) and heatmap of leading-edge genes (right). The DEG ranks were projected onto two gene sets defined based on a previously published ChIP-seq data . pSTAT3-promoted genes, genes with stronger ChIP peaks in STAT3-WT mice. (B) Relative expression of stemness genes Tcf7 , Bach2 , Il7r , Slamf6 , and Sell between mouse CD8+ T cells treated with either sIL-2 or IL-2/21-Trikine. Results from one independent experiment with 3 technical replicates. ( C-F ), C57BL/6 mice bearing established s.c. B16F10 tumors received intravenous (i.v.) adoptive cell transfer (ACT) of pmel CD8+ T cells (1 x 10 7 ) that were preconditioned for 7 days with sIL-2, sIL-2 + IL-21, or IL-2/21-Trikine on day 5, followed by i.p. injections of cytokine (5 μg functional cytokine) every other day until day 12 (n = 5 animals); the experimental timeline (C), average tumor growth curves (D), average weight change curves (E), and survival curves (F). Results from one independent experiment. ( G-I ) Healthy C57BL/6 mice were dosed with 10 μg functional dose of sIL-2, IL-21, sIL-2 + IL-21, IL-2/21-Trikine or PBS every other day for four total doses (n = 10 mice); experimental timeline (G) percent weight change at study endpoint (H), serum amyloid A concentrations at study endpoint (I). Results are combined from 2 independent experiments. ( J-M ), C57BL/6 mice bearing established s.c. B16F10 tumors received intravenous (i.v.) adoptive cell transfer (ACT) of pmel CD8+ T cells (1 x 10 7 ) that were preconditioned for 7 days with sIL-2, sIL-2 + IL-21, or IL-2/21-Trikine on day 5, followed by i.p. injections of cytokine (2.5 μg functional cytokine) every other day until day 12 (n = 14/15 animals); the experimental timeline (J), average tumor growth curves (K), average weight change curves (L), and survival curves (M). Results are combined from 2 independent experiments. ( N ) Proportions of pmel T cell memory populations, TCM and TEM in the draining lymph node 16 days post tumor injection from mice receiving low dose regimen (J-M) (n = 8). Results representative of 2 independent experiments. ( O-P ) MFI of Sca1 (O) and IL7Ra (P) cells in the draining lymph node 12 days post ACT compared to on the day of ACT from mice receiving low dose regimen (J) (n = 8). Results representative of 2 independent experiments. ( Q ) Intratumoral, live Thy1.1+CD8+ cells were sorted from dissociated tumor 12 days after ACT as in (J) and sent for scRNA-seq. 8 transcriptionally distinct clusters are seen by UMAP (left) and cluster composition by treatment is displayed (right). scRNAseq data is from one independent experiment. Schematics in C, G, and J created using BioRender.com .

    Article Snippet: For experiments performed at Stanford University, five- to six-week-old Thy1.2 + C57BL/6 (C57BL/6J) mice and B6129SF1/J (F1, Strain #101043) mice were purchased from Jackson Laboratory.

    Techniques: Isolation, RNA sequencing, ChIP-sequencing, Expressing, Functional Assay, Injection

    ( A-C ), C57BL/6 mice bearing established s.c. B16F10 tumors received intravenous (i.v.) adoptive cell transfer (ACT) of pmel CD8 + T cells (5 × 10 6 ) on day 5, followed by i.p. injections of cytokine (3 μg functional cytokine) or PBS every other day until day 20 (n = 5 animals); the experimental timeline (A), average tumor growth curves (B), and survival curves (C). Results representative of 2 independent experiments. ( D-I ) Experimental setting is described in . C57BL/6 mice bearing established s.c. B16F10 tumors received i.v. ACT of pmel CD8 + T cells (5 × 10 6 ) on day 9, followed by i.p. injections of cytokine (3 μg functional cytokine) or left NT on days 9 and 11 (n = 5 animals). Mice were sacrificed on day 13, tumors were collected for flow cytometry analysis. Frequencies of Thy1.1 + CD8 + tumor-infiltrating lymphocytes (TILs) among single-live cells (D), frequencies of SCA-1 + CD62L + cells among Thy1.1 + CD8 + TILs (E), frequencies of PD-1+CD44+ cells among Thy1.1+CD8+ TILs (F) frequencies of Granzyme B+ cells among PD-1+CD44+ Thy1.1+CD8+ TILs (G), frequencies of IFN-γ+ cells among PD-1+CD44+ Thy1.1+CD8+ TILs (H), frequencies of TCF1+TIM-3- cells among PD-1+CD44+ Thy1.1+CD8+ TILs (I). Results representative of 2 independent experiments. ( J-L ), C57BL/6 mice bearing established s.c. B16F10 tumors (n = 5-10 animals) were administered cytokine (3 μg functional cytokine), PBS, or left NT i.p. on day 5 and every other day until day 19. For combination therapy, anti-PD-1 antibody (200 μg per dose) were i.p. administered on days 7, 11, 15, and 19; the experimental timeline (J), average tumor growth curves (K), survival curves (L). Results representative of 2 independent experiments. ( M ) Schematic of patient-derived organoid experiment. ( N ) Percentages of T133 tumor organoid viability in experiment as in (M). Results representative of 2 independent experiments. All data represent mean ± s.e.m. and are analyzed by one-way (D-I, N) or two-way (B, K) ANOVA with Tukey’s post-test. Schematics in D and M created using BioRender.com .

    Journal: Science (New York, N.Y.)

    Article Title: Rewiring STAT signaling from the cell surface with Trikine immunotherapeutics

    doi: 10.1126/science.adx9954

    Figure Lengend Snippet: ( A-C ), C57BL/6 mice bearing established s.c. B16F10 tumors received intravenous (i.v.) adoptive cell transfer (ACT) of pmel CD8 + T cells (5 × 10 6 ) on day 5, followed by i.p. injections of cytokine (3 μg functional cytokine) or PBS every other day until day 20 (n = 5 animals); the experimental timeline (A), average tumor growth curves (B), and survival curves (C). Results representative of 2 independent experiments. ( D-I ) Experimental setting is described in . C57BL/6 mice bearing established s.c. B16F10 tumors received i.v. ACT of pmel CD8 + T cells (5 × 10 6 ) on day 9, followed by i.p. injections of cytokine (3 μg functional cytokine) or left NT on days 9 and 11 (n = 5 animals). Mice were sacrificed on day 13, tumors were collected for flow cytometry analysis. Frequencies of Thy1.1 + CD8 + tumor-infiltrating lymphocytes (TILs) among single-live cells (D), frequencies of SCA-1 + CD62L + cells among Thy1.1 + CD8 + TILs (E), frequencies of PD-1+CD44+ cells among Thy1.1+CD8+ TILs (F) frequencies of Granzyme B+ cells among PD-1+CD44+ Thy1.1+CD8+ TILs (G), frequencies of IFN-γ+ cells among PD-1+CD44+ Thy1.1+CD8+ TILs (H), frequencies of TCF1+TIM-3- cells among PD-1+CD44+ Thy1.1+CD8+ TILs (I). Results representative of 2 independent experiments. ( J-L ), C57BL/6 mice bearing established s.c. B16F10 tumors (n = 5-10 animals) were administered cytokine (3 μg functional cytokine), PBS, or left NT i.p. on day 5 and every other day until day 19. For combination therapy, anti-PD-1 antibody (200 μg per dose) were i.p. administered on days 7, 11, 15, and 19; the experimental timeline (J), average tumor growth curves (K), survival curves (L). Results representative of 2 independent experiments. ( M ) Schematic of patient-derived organoid experiment. ( N ) Percentages of T133 tumor organoid viability in experiment as in (M). Results representative of 2 independent experiments. All data represent mean ± s.e.m. and are analyzed by one-way (D-I, N) or two-way (B, K) ANOVA with Tukey’s post-test. Schematics in D and M created using BioRender.com .

    Article Snippet: For experiments performed at Stanford University, five- to six-week-old Thy1.2 + C57BL/6 (C57BL/6J) mice and B6129SF1/J (F1, Strain #101043) mice were purchased from Jackson Laboratory.

    Techniques: Functional Assay, Flow Cytometry, Derivative Assay

    ( A-B ), C57BL/6 mice bearing established s.c. B16F10 tumors received i.p. injections of PBS, mono-IL-10, or IL-10/2-trikine (equivalent to 3 μg functional IL-10) starting on day 5, administered every other day until day 19 (n = 9 animals); the experimental timeline (A) and average tumor growth curves (B). Results are combined from 2 independent experiments. ( C-L ), C57BL/6 mice bearing established s.c. B16F10 tumors received i.p. injections of cytokine (3 μg functional cytokine) or left NT on days 9 and 11 (n = 5 animals). Mice were sacrificed on day 13, tumors were collected for flow cytometry analysis. (C), Average frequencies of CD45 + cells among single-live cells. (D- F), Counts of CD8 + T cells (D), CD4 + T cells (E), NK cells (F), myeloid cells (G), macrophages (H), monocytes (I), CD103 + dendritic cells (J), CD11b + dendritic cells (K), and B cells (L) per mg of tumor tissue. Results are representative of 2 independent experiments. ( M-O ), C57BL/6 mice bearing established subcutaneous C2 pancreatic tumors were treated intraperitoneally with cytokine (5.6 μg functional cytokine per dose) or left untreated (NT), administered every other day from day 6 to day 20 (n = 5 mice per group); experimental timeline (M), average tumor growth curves (N) and survival curves (O) of female mice in experiment described in (M). Results are representative of 2 independent experiments. Indicated statistical significance is IL-10/2-Trikine vs. PBS, IL-10/2-Trikine vs. ICB, and IL-10/2-Trikine vs. mono-IL-10. Indicated statistical significance in (O) is mono-IL-10 vs. PBS, is IL-10/2-Trikine vs. PBS, IL-10/2-Trikine vs. ICB, and IL-10/2-Trikine vs. mono-IL-10. Data represent mean ± s.e.m. and are analyzed by one-way (C to L) or two-way (B, N) ANOVA with Tukey’s post-test. Schematics in A and M created using BioRender.com . ( P-T ) C57BL/6 mice were inoculated subcutaneously. with 2.5 × 10 5 6694c2vTRP1 cells and treated with PBS, mono-IL-10 (26 μg/mouse, n = 5), or IL-10/2-Trikine (30.6 μg/mouse, n = 5) intraperitoneally on days 8 and 10 post-inoculation. Tumors were harvested on day 14 and CD45+ cells were isolated by magnetic bead separation, individually labeled with hashtag antibodies, pooled by treatment group, and subjected to Single Cell 5' RNA and cell surface protein sequencing. (P) UMAP of tumor-infiltrating CD3 + T and NK cells colored by unsupervised clusters. (Q) Bar graph shows cell cluster composition across treatment groups. Statistical significance was assessed by unpaired t test. Black asterisks indicate comparisons between PBS and IL-10/2-Trikine; white asterisks indicate comparisons between IL-10 and IL-10/2-Trikine. *P < 0.05, **P < 0.01. (R) Gene Set Enrichment Analysis (GSEA) of differentially expressed genes (DEGs) between all clusters from IL-10/2-Trikine–treated and mono–IL-10–treated groups using MSigDB Hallmark gene sets. (S) UMAP of tumor-infiltrating T/NK cells colored by a STAT5 target gene expression score ( Gzmb , Prf1 , Nkg7 , Gzma , Klrd1 , Klrb1c , Klra7 , Ccr5 , Ly6a , Thy1 ). (T) Mean STAT5 scores per mouse across all clusters, normalized per mouse. Each dot represents one mouse; error bars indicate standard deviation. Statistical significance was assessed by Wilcoxon test. **P < 0.01. scRNAseq data are the result of one independent experiment.

    Journal: Science (New York, N.Y.)

    Article Title: Rewiring STAT signaling from the cell surface with Trikine immunotherapeutics

    doi: 10.1126/science.adx9954

    Figure Lengend Snippet: ( A-B ), C57BL/6 mice bearing established s.c. B16F10 tumors received i.p. injections of PBS, mono-IL-10, or IL-10/2-trikine (equivalent to 3 μg functional IL-10) starting on day 5, administered every other day until day 19 (n = 9 animals); the experimental timeline (A) and average tumor growth curves (B). Results are combined from 2 independent experiments. ( C-L ), C57BL/6 mice bearing established s.c. B16F10 tumors received i.p. injections of cytokine (3 μg functional cytokine) or left NT on days 9 and 11 (n = 5 animals). Mice were sacrificed on day 13, tumors were collected for flow cytometry analysis. (C), Average frequencies of CD45 + cells among single-live cells. (D- F), Counts of CD8 + T cells (D), CD4 + T cells (E), NK cells (F), myeloid cells (G), macrophages (H), monocytes (I), CD103 + dendritic cells (J), CD11b + dendritic cells (K), and B cells (L) per mg of tumor tissue. Results are representative of 2 independent experiments. ( M-O ), C57BL/6 mice bearing established subcutaneous C2 pancreatic tumors were treated intraperitoneally with cytokine (5.6 μg functional cytokine per dose) or left untreated (NT), administered every other day from day 6 to day 20 (n = 5 mice per group); experimental timeline (M), average tumor growth curves (N) and survival curves (O) of female mice in experiment described in (M). Results are representative of 2 independent experiments. Indicated statistical significance is IL-10/2-Trikine vs. PBS, IL-10/2-Trikine vs. ICB, and IL-10/2-Trikine vs. mono-IL-10. Indicated statistical significance in (O) is mono-IL-10 vs. PBS, is IL-10/2-Trikine vs. PBS, IL-10/2-Trikine vs. ICB, and IL-10/2-Trikine vs. mono-IL-10. Data represent mean ± s.e.m. and are analyzed by one-way (C to L) or two-way (B, N) ANOVA with Tukey’s post-test. Schematics in A and M created using BioRender.com . ( P-T ) C57BL/6 mice were inoculated subcutaneously. with 2.5 × 10 5 6694c2vTRP1 cells and treated with PBS, mono-IL-10 (26 μg/mouse, n = 5), or IL-10/2-Trikine (30.6 μg/mouse, n = 5) intraperitoneally on days 8 and 10 post-inoculation. Tumors were harvested on day 14 and CD45+ cells were isolated by magnetic bead separation, individually labeled with hashtag antibodies, pooled by treatment group, and subjected to Single Cell 5' RNA and cell surface protein sequencing. (P) UMAP of tumor-infiltrating CD3 + T and NK cells colored by unsupervised clusters. (Q) Bar graph shows cell cluster composition across treatment groups. Statistical significance was assessed by unpaired t test. Black asterisks indicate comparisons between PBS and IL-10/2-Trikine; white asterisks indicate comparisons between IL-10 and IL-10/2-Trikine. *P < 0.05, **P < 0.01. (R) Gene Set Enrichment Analysis (GSEA) of differentially expressed genes (DEGs) between all clusters from IL-10/2-Trikine–treated and mono–IL-10–treated groups using MSigDB Hallmark gene sets. (S) UMAP of tumor-infiltrating T/NK cells colored by a STAT5 target gene expression score ( Gzmb , Prf1 , Nkg7 , Gzma , Klrd1 , Klrb1c , Klra7 , Ccr5 , Ly6a , Thy1 ). (T) Mean STAT5 scores per mouse across all clusters, normalized per mouse. Each dot represents one mouse; error bars indicate standard deviation. Statistical significance was assessed by Wilcoxon test. **P < 0.01. scRNAseq data are the result of one independent experiment.

    Article Snippet: For experiments performed at Stanford University, five- to six-week-old Thy1.2 + C57BL/6 (C57BL/6J) mice and B6129SF1/J (F1, Strain #101043) mice were purchased from Jackson Laboratory.

    Techniques: Functional Assay, Flow Cytometry, Isolation, Labeling, Single Cell, Sequencing, Targeted Gene Expression, Standard Deviation

    (A) Quantification of total CD4 + and CD8 + T cells in the lungs of mice treated with anti-Thy1.2 depleting Abs (orange) or IgG control Abs (gray). Statistical significance was determined by the student’s t-test. Boxes indicate interquartile range with a line drawn at the mean; whiskers indicate the minimum and maximum values. (B) T RM content in the lungs of T cell-depleted or control mice in (A) shown in representative flow cytometry plots (left) and compiled results (right) of CD45 expression from i.v. Ab administration (CD45(IV), left) and CD69 expression (right) by CD4 + (top), and CD8 + (bottom) T cells. (C) Lung macrophage accumulation after influenza infection in T RM -depleted (blue) and control (green) mice undergoing secondary infection at 4dpi compared to uninfected counterparts shown in representative flow cytometry plots (left) and compiled results (right) of F4/80 + macrophages in the lungs. Statistical significance for (A-C) was determined by the student’s t-test. (D-E) Pearson correlation analyses between T RM and CD4 + and CD8 + T RM subsets with (D) macrophages and with (E) Arg1 + macrophages. Data are representative of two independent experiments, with n=7–10 mice per group. ****, p ≤ 0.0001; ***; p ≤ 0.001; **, p ≤ 0.01; *, p ≤ 0.05.

    Journal: The Journal of experimental medicine

    Article Title: Lung tissue-resident memory T cells optimize protection by IL-10 regulation of innate immunity

    doi: 10.1084/jem.20242307

    Figure Lengend Snippet: (A) Quantification of total CD4 + and CD8 + T cells in the lungs of mice treated with anti-Thy1.2 depleting Abs (orange) or IgG control Abs (gray). Statistical significance was determined by the student’s t-test. Boxes indicate interquartile range with a line drawn at the mean; whiskers indicate the minimum and maximum values. (B) T RM content in the lungs of T cell-depleted or control mice in (A) shown in representative flow cytometry plots (left) and compiled results (right) of CD45 expression from i.v. Ab administration (CD45(IV), left) and CD69 expression (right) by CD4 + (top), and CD8 + (bottom) T cells. (C) Lung macrophage accumulation after influenza infection in T RM -depleted (blue) and control (green) mice undergoing secondary infection at 4dpi compared to uninfected counterparts shown in representative flow cytometry plots (left) and compiled results (right) of F4/80 + macrophages in the lungs. Statistical significance for (A-C) was determined by the student’s t-test. (D-E) Pearson correlation analyses between T RM and CD4 + and CD8 + T RM subsets with (D) macrophages and with (E) Arg1 + macrophages. Data are representative of two independent experiments, with n=7–10 mice per group. ****, p ≤ 0.0001; ***; p ≤ 0.001; **, p ≤ 0.01; *, p ≤ 0.05.

    Article Snippet: To deplete T RM from mice, WT mice were infected with X31 influenza virus as above and 3 weeks post infection (wkpi), the resultant memory mice were administered 10μg/g of Thy1.2-depleting antibody (BioXcell; BE0066) by intraperitoneal (IP) injection four times over the course of one week.

    Techniques: Control, Flow Cytometry, Expressing, Infection